In this context, demcizumab, an IgG2 humanized monoclonal antibody directed against Dll4, was initially tested in combinational therapies with pemetrexed and carboplatin in non-squamous NSCLC, where 20 out of 40 patients had objective tumor response [166], although, unfortunately however, showed no benefit in a more recent, completed Phase 2 study (NCT02259582). Here, DLL4 is linked to neoplasm.